Latest filing published 03 Apr 2025 for Unity Biotechnology, Inc., €91k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Anirvan Ghosh in Unity Biotechnology, Inc., where the filings describe the role as chief executive. The record holds 33 filings, for trades running from 24 June 2021 to 2 April 2025.
Sales make up the whole of the open-market record (26 sales, €170k). Other entries cover 7 share grants. Since January 2025: no purchases and 2 sales on the market.
On 3 April 2025 came the latest disclosure, an open-market sale for €91k in Unity Biotechnology, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 33 declarations